Cuprina Holdings (Cayman) Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Monitoring Framework
Key Performance Indicators
Annual Revenue (SGD) Annually49.9K
Net Loss (SGD) Annually-4.7M
Cash and Cash Equivalents (USD) Quarterly2.5M
Watch Items
- Nasdaq Minimum Bid Price ComplianceTrigger: Closing bid price below $1.00 for 30 consecutive business daysAction: Implement share consolidation or reverse stock split to regain compliance
- Commercialization of MEDIFLY Maggots in the USTrigger: U.S. FDA 510(k) clearance received on June 15, 2026Action: Initiate marketing, distribution, and sales operations in the United States
- Saudi Arabia Laboratory and Product RegistrationTrigger: SFDA product classification received for MEDIFLYAction: Complete ISO 13485 certification and secure final SFDA registration to begin Middle East distribution
Research as of 20 Jun 2026